OnKure Therapeutics, Inc.
OKUR
$3.99
$0.092.31%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.55% | -2.01% | -17.21% | 156.88% | 3.34% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 3.52% | -8.15% | -20.88% | 34.65% | 18.97% |
| Operating Income | -3.52% | 8.15% | 20.88% | -34.65% | -18.97% |
| Income Before Tax | 0.29% | 4.82% | 22.58% | -27.20% | -8.85% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 0.29% | 4.82% | 22.58% | -27.20% | -8.85% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 0.29% | 4.82% | 22.58% | -27.20% | -8.85% |
| EBIT | -3.52% | 8.15% | 20.88% | -34.65% | -18.97% |
| EBITDA | -3.73% | 8.12% | 20.95% | -35.09% | -19.09% |
| EPS Basic | 72.99% | 6.57% | 27.27% | 97.03% | 97.46% |
| Normalized Basic EPS | 72.99% | 6.56% | 23.02% | 97.03% | 97.34% |
| EPS Diluted | 72.99% | 6.57% | 27.27% | 97.03% | 97.46% |
| Normalized Diluted EPS | 72.99% | 6.56% | 23.02% | 97.03% | 97.34% |
| Average Basic Shares Outstanding | 269.15% | 1.86% | 6.44% | 4,180.58% | 4,181.81% |
| Average Diluted Shares Outstanding | 269.15% | 1.86% | 6.44% | 4,180.58% | 4,181.81% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |